Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects

J Clin Pharmacol. 2021 Jul;61(7):913-922. doi: 10.1002/jcph.1805. Epub 2021 Jan 12.

Abstract

This clinical trial was conducted to evaluate the pharmacokinetics and pharmacodynamics of tegoprazan when coadministered with amoxicillin/clarithromycin in healthy subjects. Cohort 1 was an open-label, randomized multiple-dose study to evaluate the mutual interaction of tegoprazan and amoxicillin/clarithromycin on the disposition of 3 tested drugs including tegoprazan M1 metabolite and 14-hydroxyclarithromycin (14-OH-clarithromycin). Cohort 2 was an open-label, randomized, active-controlled, parallel multiple-dose study to compare the intragastric pH profile after multiple oral doses of 50 or 100 mg tegoprazan coadministered with amoxicillin/clarithromycin 1000/500 mg for 7 days and pantoprazole-based triple therapy as the comparator arm. The coadministration of tegoprazan with amoxicillin/clarithromycin increased Css,max (2.2-fold) and AUCτ (2.7-fold) of tegoprazan and M1 (2.1- and 2.2-fold for Css,max and AUCτ , respectively) compared with administration of tegoprazan alone. The Css,max and AUCτ of 14-OH-clarithromycin increased by 1.7- and 1.8-fold, respectively; the disposition of amoxicillin and clarithromycin were not significantly changed. On days 1 and 7 of treatment, tegoprazan-based therapies (both 50- and 100-mg therapies) maintained pH above 6 for more than 88% of the 24-hour period, which was significantly longer compared with pantoprazole-based therapy. Tegoprazan either alone or in combination with amoxicillin/clarithromycin was well tolerated in healthy subjects. In conclusion, the exposure of tegoprazan was increased after coadministration of amoxicillin/clarithromycin, which led to increase pharmacodynamic response measured by intragastric pH compared with tegoprazan alone. Therefore, tegoprazan-based triple therapy would be effective therapeutic regimen to manage intragastric pH in terms of gastric or duodenal ulcers healing, treatment of gastroesophageal reflux disease, and Helicobacter pylori eradication.

Keywords: drug interaction; pharmacodynamics; pharmacokinetics; tegoprazan.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amoxicillin / administration & dosage
  • Amoxicillin / pharmacokinetics*
  • Amoxicillin / pharmacology
  • Area Under Curve
  • Benzene Derivatives / administration & dosage
  • Benzene Derivatives / pharmacokinetics*
  • Benzene Derivatives / pharmacology
  • Clarithromycin / administration & dosage
  • Clarithromycin / analogs & derivatives
  • Clarithromycin / metabolism
  • Clarithromycin / pharmacokinetics*
  • Clarithromycin / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / pharmacokinetics*
  • Gastrointestinal Agents / pharmacology
  • Healthy Volunteers
  • Humans
  • Hydrogen-Ion Concentration
  • Imidazoles / administration & dosage
  • Imidazoles / pharmacokinetics*
  • Imidazoles / pharmacology
  • Male
  • Metabolic Clearance Rate
  • Middle Aged

Substances

  • Benzene Derivatives
  • Drug Combinations
  • Gastrointestinal Agents
  • Imidazoles
  • 14-hydroxyclarithromycin
  • Amoxicillin
  • Clarithromycin
  • tegoprazan